Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
Open Access
- 7 January 2021
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 11 (1) , 1-11
Abstract
Autologous stem cell transplant (aHSCT) is associated with improved survival for multiple myeloma (MM) patients but may be associated with second primary malignancy (SPM) development. Using the California Cancer Registry linked to statewide hospitalization data, we determined the cumulative incidence (CMI) of SPMs more than 1 year after MM diagnosis, accounting for the competing risk of death. AHSCT recipients were matched 1:2 to non-aHSCT patients. Adjusted hazard ratios (aHR) were estimated using the Fine and Gray method. Among 16,331 patients, 933 (5.7%) developed a SPM more than 1 year after diagnosis. The 10-year CMI of developing any SPM was 6.6%, 5.7% for solid tumor SPM and 0.9% for hematologic malignancies. The 10-year CMI of developing any SPM was similar among aHSCT [9.1% (7.7–10.7%)] and non-aHSCT [7.5% (6.5–8.6%)] (P = 0.26) recipients and there was no difference in solid-tumor SPMs (P = 0.98). The 10-year CMI of hematologic SPMs was higher among aHSCT recipients [2.1% (1.4–2.9%) vs. 0.8% (0.5–1.2%); P = 0.005], corresponding to a 1.3% absolute increase and an aHR of 1.51 (1.01–2.27). Ten-year myeloma-specific and non-cancer mortality rates were 59% (58.2–60.0%) and 18.1% (17.4–18.8%), respectively. Although aHSCT was associated with a small increase in hematologic SPMs, mortality was driven by MM and non-cancer causes.Keywords
This publication has 43 references indexed in Scilit:
- Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population–Based StudyPLOS ONE, 2013
- Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeuticsBlood Cancer Journal, 2013
- Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United StatesJournal of Clinical Oncology, 2013
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Blood, 2011
- Survivorship Care Guidelines for Patients Living With Multiple MyelomaClinical Journal of Oncology Nursing, 2011
- Routine Health Maintenance in Patients Living With Multiple MyelomaClinical Journal of Oncology Nursing, 2011
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Understanding and Enhancing the Value of Hospital Discharge DataMedical Care Research and Review, 2007
- Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myelomaBritish Journal of Haematology, 1996
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996